Genesis Healthcare Inc. Aktie
Finanztrends
Genesis Healthcare Inc. Aktie
Genesis Healthcare Inc. ist derzeit einer der Favoriten unserer Community mit 7 Buy-Einschätzungen und keiner einzigen Sell-Einschätzung.
Für Genesis Healthcare Inc. sieht die Community ein Kursziel von 32 €, was mehr als das Doppelte des aktuellen Kurses von 0.38 € ausmacht.
Was spricht für und gegen Genesis Healthcare Inc. in den nächsten Jahren?
Pro
?
M****
?
L*********** I********** f** d** n******* J****
?
A****************
Kontra
?
U****************
?
W******* i* V********
?
M************
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Genesis Healthcare Inc. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Genesis Healthcare Inc. | - | - | - | - | - | - | - |
| Capital Senior Living Corp. | -0,69 % | -10,06 % | -11,18 % | 36,19 % | 5,93 % | - | - |
| Healthstream Inc. | 0,00 % | 3,85 % | 22,73 % | -11,48 % | 10,77 % | -3,57 % | 0,93 % |
| Evolent Health Inc | 0,00 % | 6,92 % | 6,25 % | -48,09 % | -0,58 % | -88,19 % | - |
Kommentare
News
Cellebrite DI Eyes AI, Cloud and FedRAMP as Digital Investigations Demand Grows
Cellebrite DI (NASDAQ:CLBT) executives said the company is seeing broader customer adoption of its digital investigations platform, with artificial intelligence, cloud migration and U.S. federal
Cellebrite DI Sees Federal Rebound as AI, Defense Tools Fuel New Growth
Key Points
- Interested in Cellebrite DI Ltd.? Here are five stocks we like better.
- Federal demand is rebounding after weakness in 2025, when Cellebrite’s U.S. federal business was essentially
Cellebrite DI Q1 Earnings Call Highlights
Cellebrite DI (NASDAQ:CLBT) reported first-quarter 2026 results that management said met or exceeded the high end of its guidance for annual recurring revenue and adjusted EBITDA, while executives